{"entity":{"type":"insider","cik":"0001423837","url":"/insider/0001423837","json_url":"/insider/0001423837.json","name":"Bozigian Haig P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":91,"n_filings":58,"first":"2008-02-06","last":"2021-02-09","span_basis":"filed_date"},"name_variants":[{"name":"Bozigian Haig P.","source":"filing","n_filings":58,"first_seen":"2008-02-06","last_seen":"2021-02-09"}],"transactions":[{"id":5091785,"accession":"0001209191-21-009130","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-009130","line_url":"/filing/0001209191-21-009130","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3842.0,"shares_display":"3,842","price_per_share":116.80077574180115,"price_display":"116.80","price_state":"stated","total_value":448748.5804,"total_display":"448,748.58","total_whole":"448,749","shares_owned_after":157651.0,"shares_owned_after_display":"157,651","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-08","filed_date":"2021-02-09","scope":"insider","n_lines":3},{"id":5091769,"accession":"0001209191-21-009130","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-009130","line_url":"/filing/0001209191-21-009130#line-1","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":704.0,"shares_display":"704","price_per_share":113.7905,"price_display":"113.79","price_state":"stated","total_value":80108.512,"total_display":"80,108.51","total_whole":"80,109","shares_owned_after":153328.0,"shares_owned_after_display":"153,328","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-05","filed_date":"2021-02-09","scope":"insider"},{"id":2797621,"accession":"0001209191-20-058539","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-058539","line_url":"/filing/0001209191-20-058539#line-1","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2257.0,"shares_display":"2,257","price_per_share":90.7428,"price_display":"90.74","price_state":"stated","total_value":204806.4996,"total_display":"204,806.50","total_whole":"204,806","shares_owned_after":152694.0,"shares_owned_after_display":"152,694","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-12","filed_date":"2020-11-16","scope":"insider"},{"id":3116006,"accession":"0001209191-20-045742","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-045742","line_url":"/filing/0001209191-20-045742#line-1","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2257.0,"shares_display":"2,257","price_per_share":118.8854,"price_display":"118.89","price_state":"stated","total_value":268324.3478,"total_display":"268,324.35","total_whole":"268,324","shares_owned_after":150663.0,"shares_owned_after_display":"150,663","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-08-05","filed_date":"2020-08-07","scope":"insider"},{"id":2898290,"accession":"0001209191-20-029401","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-20-029401","line_url":"/filing/0001209191-20-029401","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":61555.0,"shares_display":"61,555","price_per_share":114.9443,"price_display":"114.94","price_state":"stated","total_value":7075396.3865,"total_display":"7,075,396.39","total_whole":"7,075,396","shares_owned_after":148633.0,"shares_owned_after_display":"148,633","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-05-12","filed_date":"2020-05-14","scope":"insider","n_lines":4},{"id":2897655,"accession":"0001209191-20-026064","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-026064","line_url":"/filing/0001209191-20-026064#line-1","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1934.0,"shares_display":"1,934","price_per_share":99.4577,"price_display":"99.46","price_state":"stated","total_value":192351.1918,"total_display":"192,351.19","total_whole":"192,351","shares_owned_after":148633.0,"shares_owned_after_display":"148,633","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-04-24","filed_date":"2020-04-28","scope":"insider"},{"id":3188319,"accession":"0001209191-20-008484","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-008484","line_url":"/filing/0001209191-20-008484#line-1","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1623.0,"shares_display":"1,623","price_per_share":103.3282,"price_display":"103.33","price_state":"stated","total_value":167701.6686,"total_display":"167,701.67","total_whole":"167,702","shares_owned_after":146641.0,"shares_owned_after_display":"146,641","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-02-07","filed_date":"2020-02-11","scope":"insider"},{"id":2283674,"accession":"0001209191-20-007674","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-20-007674","line_url":"/filing/0001209191-20-007674#line-3","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1395.0,"shares_display":"1,395","price_per_share":101.5556,"price_display":"101.56","price_state":"stated","total_value":141670.062,"total_display":"141,670.06","total_whole":"141,670","shares_owned_after":145180.0,"shares_owned_after_display":"145,180","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-02-06","filed_date":"2020-02-07","scope":"insider"},{"id":2283671,"accession":"0001209191-20-007674","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-007674","line_url":"/filing/0001209191-20-007674","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2046.0,"shares_display":"2,046","price_per_share":103.01999354838709,"price_display":"103.02","price_state":"stated","total_value":210778.9068,"total_display":"210,778.91","total_whole":"210,779","shares_owned_after":143292.0,"shares_owned_after_display":"143,292","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-02-05","filed_date":"2020-02-07","scope":"insider","n_lines":2},{"id":8418380,"accession":"0001209191-19-043914","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-19-043914","line_url":"/filing/0001209191-19-043914","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":44356.0,"shares_display":"44,356","price_per_share":92.76890670033366,"price_display":"92.77","price_state":"stated","total_value":4114857.6256,"total_display":"4,114,857.63","total_whole":"4,114,858","shares_owned_after":141976.0,"shares_owned_after_display":"141,976","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-07-30","filed_date":"2019-07-31","scope":"insider","n_lines":2},{"id":7927617,"accession":"0001209191-19-042522","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-042522","line_url":"/filing/0001209191-19-042522#line-2","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30680.0,"shares_display":"30,680","price_per_share":87.5002,"price_display":"87.50","price_state":"stated","total_value":2684506.136,"total_display":"2,684,506.14","total_whole":"2,684,506","shares_owned_after":141976.0,"shares_owned_after_display":"141,976","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-07-15","filed_date":"2019-07-17","scope":"insider"},{"id":8350577,"accession":"0001209191-19-041925","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-19-041925","line_url":"/filing/0001209191-19-041925#line-4","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100.0,"shares_display":"100","price_per_share":87.59,"price_display":"87.59","price_state":"stated","total_value":8759.0,"total_display":"8,759.00","total_whole":"8,759","shares_owned_after":141976.0,"shares_owned_after_display":"141,976","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-07-11","filed_date":"2019-07-12","scope":"insider"},{"id":8350571,"accession":"0001209191-19-041925","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-041925","line_url":"/filing/0001209191-19-041925#line-2","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7120.0,"shares_display":"7,120","price_per_share":87.6345,"price_display":"87.63","price_state":"stated","total_value":623957.64,"total_display":"623,957.64","total_whole":"623,958","shares_owned_after":141976.0,"shares_owned_after_display":"141,976","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-07-10","filed_date":"2019-07-12","scope":"insider"},{"id":8101064,"accession":"0001209191-19-038288","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-038288","line_url":"/filing/0001209191-19-038288#line-2","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2100.0,"shares_display":"2,100","price_per_share":87.8174,"price_display":"87.82","price_state":"stated","total_value":184416.54,"total_display":"184,416.54","total_whole":"184,417","shares_owned_after":141976.0,"shares_owned_after_display":"141,976","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-06-18","filed_date":"2019-06-20","scope":"insider"},{"id":8119774,"accession":"0001209191-19-037472","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-19-037472","line_url":"/filing/0001209191-19-037472","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17268.0,"shares_display":"17,268","price_per_share":82.61685253648366,"price_display":"82.62","price_state":"stated","total_value":1426627.8096,"total_display":"1,426,627.81","total_whole":"1,426,628","shares_owned_after":141976.0,"shares_owned_after_display":"141,976","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-06-13","filed_date":"2019-06-17","scope":"insider","n_lines":2},{"id":8026942,"accession":"0001209191-19-034913","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-034913","line_url":"/filing/0001209191-19-034913#line-2","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3435.0,"shares_display":"3,435","price_per_share":85.5076,"price_display":"85.51","price_state":"stated","total_value":293718.606,"total_display":"293,718.61","total_whole":"293,719","shares_owned_after":141976.0,"shares_owned_after_display":"141,976","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-06-03","filed_date":"2019-06-05","scope":"insider"},{"id":8618544,"accession":"0001209191-19-034056","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-034056","line_url":"/filing/0001209191-19-034056#line-2","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":19297.0,"shares_display":"19,297","price_per_share":85.0174,"price_display":"85.02","price_state":"stated","total_value":1640580.7678,"total_display":"1,640,580.77","total_whole":"1,640,581","shares_owned_after":141976.0,"shares_owned_after_display":"141,976","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-31","filed_date":"2019-06-03","scope":"insider"},{"id":8318677,"accession":"0001209191-19-033260","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-033260","line_url":"/filing/0001209191-19-033260#line-2","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17486.0,"shares_display":"17,486","price_per_share":80.0317,"price_display":"80.03","price_state":"stated","total_value":1399434.3062,"total_display":"1,399,434.31","total_whole":"1,399,434","shares_owned_after":141976.0,"shares_owned_after_display":"141,976","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-24","filed_date":"2019-05-29","scope":"insider"},{"id":8417461,"accession":"0001209191-19-032451","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-032451","line_url":"/filing/0001209191-19-032451#line-2","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1300.0,"shares_display":"1,300","price_per_share":80.0285,"price_display":"80.03","price_state":"stated","total_value":104037.05,"total_display":"104,037.05","total_whole":"104,037","shares_owned_after":141976.0,"shares_owned_after_display":"141,976","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-22","filed_date":"2019-05-23","scope":"insider"},{"id":8391394,"accession":"0001209191-19-031531","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-19-031531","line_url":"/filing/0001209191-19-031531","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":66667.0,"shares_display":"66,667","price_per_share":80.128,"price_display":"80.13","price_state":"stated","total_value":5341893.376,"total_display":"5,341,893.38","total_whole":"5,341,893","shares_owned_after":141976.0,"shares_owned_after_display":"141,976","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-16","filed_date":"2019-05-20","scope":"insider","n_lines":4},{"id":8566725,"accession":"0001209191-19-030172","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-030172","line_url":"/filing/0001209191-19-030172#line-2","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":34547.0,"shares_display":"34,547","price_per_share":75.5149,"price_display":"75.51","price_state":"stated","total_value":2608813.2503,"total_display":"2,608,813.25","total_whole":"2,608,813","shares_owned_after":141976.0,"shares_owned_after_display":"141,976","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-13","filed_date":"2019-05-15","scope":"insider"},{"id":8753203,"accession":"0001209191-19-008629","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-008629","line_url":"/filing/0001209191-19-008629#line-1","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":920.0,"shares_display":"920","price_per_share":83.5428,"price_display":"83.54","price_state":"stated","total_value":76859.376,"total_display":"76,859.38","total_whole":"76,859","shares_owned_after":141639.0,"shares_owned_after_display":"141,639","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-06","filed_date":"2019-02-08","scope":"insider"},{"id":8294586,"accession":"0001209191-19-007847","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-19-007847","line_url":"/filing/0001209191-19-007847","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1350.0,"shares_display":"1,350","price_per_share":88.13809555555555,"price_display":"88.14","price_state":"stated","total_value":118986.429,"total_display":"118,986.43","total_whole":"118,986","shares_owned_after":139909.0,"shares_owned_after_display":"139,909","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-05","filed_date":"2019-02-06","scope":"insider","n_lines":2},{"id":8294576,"accession":"0001209191-19-007847","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-007847","line_url":"/filing/0001209191-19-007847#line-1","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1375.0,"shares_display":"1,375","price_per_share":88.1011,"price_display":"88.10","price_state":"stated","total_value":121139.0125,"total_display":"121,139.01","total_whole":"121,139","shares_owned_after":137372.0,"shares_owned_after_display":"137,372","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-04","filed_date":"2019-02-06","scope":"insider"},{"id":6426979,"accession":"0001209191-18-058222","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-18-058222","line_url":"/filing/0001209191-18-058222","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":36295.0,"shares_display":"36,295","price_per_share":110.0,"price_display":"110.00","price_state":"stated","total_value":3992450.0,"total_display":"3,992,450.00","total_whole":"3,992,450","shares_owned_after":135997.0,"shares_owned_after_display":"135,997","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-11-08","filed_date":"2018-11-13","scope":"insider","n_lines":2},{"id":6662681,"accession":"0001209191-18-057772","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-18-057772","line_url":"/filing/0001209191-18-057772","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":29399.0,"shares_display":"29,399","price_per_share":110.14430232320828,"price_display":"110.14","price_state":"stated","total_value":3238132.344,"total_display":"3,238,132.34","total_whole":"3,238,132","shares_owned_after":135997.0,"shares_owned_after_display":"135,997","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-11-07","filed_date":"2018-11-08","scope":"insider","n_lines":3},{"id":6662664,"accession":"0001209191-18-057772","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-057772","line_url":"/filing/0001209191-18-057772#line-2","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9420.0,"shares_display":"9,420","price_per_share":110.1027,"price_display":"110.10","price_state":"stated","total_value":1037167.434,"total_display":"1,037,167.43","total_whole":"1,037,167","shares_owned_after":135997.0,"shares_owned_after_display":"135,997","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-11-06","filed_date":"2018-11-08","scope":"insider"},{"id":6145452,"accession":"0001209191-18-017693","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-18-017693","line_url":"/filing/0001209191-18-017693","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":75873.0,"shares_display":"75,873","price_per_share":90.0,"price_display":"90.00","price_state":"stated","total_value":6828570.0,"total_display":"6,828,570.00","total_whole":"6,828,570","shares_owned_after":135997.0,"shares_owned_after_display":"135,997","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-03-05","filed_date":"2018-03-07","scope":"insider","n_lines":2},{"id":6131928,"accession":"0001209191-18-008209","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-008209","line_url":"/filing/0001209191-18-008209","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2262.0,"shares_display":"2,262","price_per_share":83.10191626878868,"price_display":"83.10","price_state":"stated","total_value":187976.5346,"total_display":"187,976.53","total_whole":"187,977","shares_owned_after":132601.0,"shares_owned_after_display":"132,601","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-02-05","filed_date":"2018-02-07","scope":"insider","n_lines":2},{"id":6630792,"accession":"0001209191-18-004235","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-004235","line_url":"/filing/0001209191-18-004235#line-1","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1625.0,"shares_display":"1,625","price_per_share":79.1229,"price_display":"79.12","price_state":"stated","total_value":128574.7125,"total_display":"128,574.71","total_whole":"128,575","shares_owned_after":131226.0,"shares_owned_after_display":"131,226","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-01-16","filed_date":"2018-01-18","scope":"insider"},{"id":5209952,"accession":"0001209191-17-052020","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-17-052020","line_url":"/filing/0001209191-17-052020","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":26250.0,"shares_display":"26,250","price_per_share":60.0,"price_display":"60.00","price_state":"stated","total_value":1575000.0,"total_display":"1,575,000.00","total_whole":"1,575,000","shares_owned_after":129601.0,"shares_owned_after_display":"129,601","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-06","filed_date":"2017-09-08","scope":"insider","n_lines":2},{"id":5209651,"accession":"0001209191-17-048144","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-17-048144","line_url":"/filing/0001209191-17-048144#line-4","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001423837","owner_name":"Bozigian Haig P.","owner_display_name":"Bozigian Haig P.","owner_url":"/insider/0001423837","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":50.0,"price_display":"50.00","price_state":"stated","total_value":1000000.0,"total_display":"1,000,000.00","total_whole":"1,000,000","shares_owned_after":129601.0,"shares_owned_after_display":"129,601","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-08-04","filed_date":"2017-08-08","scope":"insider"}],"collapsed":true,"next_cursor":"2017-08-04|5209651","ledger_fault":false,"count":{"value":91,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":91,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":91},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000914475","name":"NEUROCRINE BIOSCIENCES INC","url":"/issuer/0000914475","role":"Officer (Chief Development Officer)","n_filings":58,"first_seen":"2008-02-06","last_seen":"2021-02-09"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001423837","retrieved_at":"2026-08-25T16:14:35+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}